SG10201806809QA - 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders - Google Patents
1-heterocyclyl isochromanyl compounds and analogs for treating cns disordersInfo
- Publication number
- SG10201806809QA SG10201806809QA SG10201806809QA SG10201806809QA SG10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA SG 10201806809Q A SG10201806809Q A SG 10201806809QA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- heterocyclyl
- analogs
- isochromanyl
- cns disorders
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562115064P | 2015-02-11 | 2015-02-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201806809QA true SG10201806809QA (en) | 2018-09-27 |
Family
ID=55456908
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201806809QA SG10201806809QA (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
| SG11201706515QA SG11201706515QA (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201706515QA SG11201706515QA (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9856238B2 (enExample) |
| EP (2) | EP4046995B1 (enExample) |
| JP (3) | JP6657241B2 (enExample) |
| KR (1) | KR102601972B1 (enExample) |
| CN (2) | CN107531674B (enExample) |
| AU (1) | AU2016219253C1 (enExample) |
| CA (1) | CA2976095C (enExample) |
| CY (1) | CY1125198T1 (enExample) |
| DK (1) | DK3256466T3 (enExample) |
| EA (1) | EA201791804A1 (enExample) |
| ES (2) | ES2911910T3 (enExample) |
| HU (1) | HUE058698T2 (enExample) |
| IL (1) | IL253914B (enExample) |
| MX (2) | MX371404B (enExample) |
| MY (1) | MY188160A (enExample) |
| NZ (1) | NZ735011A (enExample) |
| PH (1) | PH12017501422A1 (enExample) |
| PL (1) | PL3256466T3 (enExample) |
| PT (1) | PT3256466T (enExample) |
| SG (2) | SG10201806809QA (enExample) |
| UA (1) | UA122222C2 (enExample) |
| WO (1) | WO2016130796A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107567454B (zh) * | 2015-02-11 | 2020-02-18 | 赛诺维信制药公司 | 用于治疗cns障碍的稠合二氢-4h-吡唑并[5,1-c][1,4]噁嗪基化合物及其类似物 |
| EA201791804A1 (ru) * | 2015-02-11 | 2018-02-28 | Суновион Фармасьютикалз Инк. | Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс |
| US10196403B2 (en) * | 2016-07-29 | 2019-02-05 | Sunovion Pharmaceuticals Inc. | Compounds and compositions and uses thereof |
| KR20190065246A (ko) | 2016-07-29 | 2019-06-11 | 선오비온 파마슈티컬스 인코포레이티드 | 화합물 및 조성물 및 이들의 용도 |
| BR112019028034A2 (pt) | 2017-06-30 | 2020-07-07 | Chase Therapeutics Corporation | composições de antagonista de nk-1 e métodos para uso no tratamento da depressão |
| JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
| US12077546B2 (en) | 2021-04-10 | 2024-09-03 | Sumitomo Pharma Co., Ltd. | Bicyclic pyridine derivative |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
| US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
| US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
| IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
| ATE252572T1 (de) | 1998-06-30 | 2003-11-15 | Lilly Co Eli | 5-ht1f agonisten |
| SE9902267D0 (sv) * | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
| RU2004117211A (ru) * | 2001-11-08 | 2005-03-27 | Сепракор, Инк. (Us) | Способы лечения депресии и других рассстройств цнс с использованием энантиомерно обогащшенных десметил-и дидесметилметаболитов циталопрама |
| CA2591810A1 (en) * | 2004-12-21 | 2006-06-29 | F.Hoffmann-La Roche Ag | Chroman derivatives and uses thereof in the treatment of cns disorders |
| TW200716595A (en) | 2005-04-22 | 2007-05-01 | Wyeth Corp | Chromane and chromene derivatives and uses thereof |
| JP2009524618A (ja) * | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ障害の処置における２−イミダゾールの使用 |
| KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
| NZ767139A (en) * | 2009-12-04 | 2022-08-26 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
| US8569339B2 (en) | 2011-03-10 | 2013-10-29 | Boehringer Ingelheim International Gmbh | Soluble guanylate cyclase activators |
| AR090557A1 (es) * | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
| EP2938341B1 (en) * | 2012-12-31 | 2018-09-05 | Sunovion Pharmaceuticals Inc. | Heterocyclic compounds and methods of use thereof |
| EA201791804A1 (ru) * | 2015-02-11 | 2018-02-28 | Суновион Фармасьютикалз Инк. | Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс |
-
2016
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh active Active
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active Active
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en not_active Ceased
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja not_active Expired - Fee Related
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en not_active Ceased
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh active Active
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en not_active IP Right Cessation
- 2016-02-11 MX MX2020001157A patent/MX392664B/es unknown
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja not_active Expired - Fee Related
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en not_active Abandoned
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
- 2022-05-20 CY CY20221100352T patent/CY1125198T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201806809QA (en) | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| PH12017501423A1 (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
| MX2022012317A (es) | Oxisteroles y metodos de uso de los mismos. | |
| MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| MX390302B (es) | Oxiesteroles y metodos de uso de los mismos | |
| MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
| MX2016010056A (es) | 6-heteroariloxi o 6-ariloxi-quinolina-2-carboxamidas y metodos de uso. | |
| PH12020551013A1 (en) | Oxy-fluoropiperidine derivative as kinase inhibitor | |
| PH12020551014A1 (en) | Amino-fluoropiperidine derivatives as kinase inhibitor | |
| MX2017003518A (es) | Estimuladores de guanilato ciclasa soluble (sgc). | |
| MX2021014531A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| WO2016087665A3 (en) | Compounds for treating cystic fibrosis | |
| HK1255500A1 (zh) | 氧固醇及其使用方法 | |
| PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| MX2021015942A (es) | Composiciones y métodos para tratar trastornos del snc. | |
| WO2017177004A8 (en) | Tertiary amides and method of use | |
| PH12017501876A1 (en) | Pyridopyrimidones and their use as nmda receptor modulators | |
| MX2022005024A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
| PH12019500822A1 (en) | Crystalline forms of eravacycline | |
| MX2017003458A (es) | Indazol ureas y metodo de uso. | |
| NZ748942A (en) | Pyrazolylaminobenzimidazole derivatives as jak inhibitors | |
| MX2019000608A (es) | Derivados de panteteina para tratamiento de trastornos neurologicos. | |
| PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 |